Sermorelin FAQ: sport, drug tests and interactions

Is sermorelin banned in sports?

Yes. Growth hormone secretagogues, including GHRH analogs such as sermorelin, are prohibited in tested sport at all times. The review of GHRH-analog detection describes the analytical work developed in that anti-doping setting.

The prohibition covers the drug class. It does not establish that sermorelin has produced a particular performance benefit in a controlled trial. I regard that reversal of a prohibited list as a peculiar shortcut. The sports-medicine review discusses restrictions alongside uncertain efficacy, safety and product quality.

Will a sermorelin drug test detect it?

Standard employment drug panels do not ordinarily look for sermorelin; specialized anti-doping methods can. The magnetic-bead enrichment and mass-spectrometry method tested GHRH analogs in human urine with a reported detection limit of 0.2 ng/mL. The nano-liquid chromatography and mass-spectrometry method included sermorelin and its primary metabolite, with detection limits of 0.5 ng/mL or lower.

Mass spectrometry helps identify substances by their mass-related analytical signals; enrichment isolates material before that measurement. The specificity of this laboratory work impresses me. An assay’s detection limit is an instrument-method result, however, and supplies no dependable timetable for an individual to test negative. The plasma half-life cannot provide that timetable either.

Is sermorelin illegal?

The U.S. record has several stages. Sermorelin had FDA approval for pediatric GH deficiency and short stature, then its branded product left the market in 2008 for commercial reasons, without a safety or efficacy withdrawal finding. The review of the resulting U.S. diagnostic gap describes the loss of a commercially available GHRH agent.

Today’s compounded preparations have no FDA approval. Sermorelin is treated as a long-standing Category 1 bulk drug substance under FDA’s interim Section 503A policy, finalized in January 2025, whose conditions still apply. A licensed clinician’s assessment and prescription precede patient-specific preparation by a pharmacy. Category 1 describes the interim policy treatment of the ingredient.

I would avoid a blanket legal answer that erases those conditions or confuses U.S. compounding with the sports prohibition. The particular preparation and circumstances still matter.

Sermorelin and Adderall

The papers listed here contain no direct clinical interaction study of sermorelin and Adderall. It therefore cannot establish that taking them together is safe, identify a specific interaction rate or support a combined regimen.

I can’t make the silence reassuring. A prescriber or pharmacist needs the actual medicines, formulation and medical history to assess that pairing. The published GH and IGF-1 changes discussed here answer a different question from the safety of combining medicines.

Does sermorelin help sleep?

Deeper sleep and vivid dreams are prominent in the supplied community accounts; grogginess also appears. Those are anecdotal reports, not clinical evidence. The hormone physiology gives a reason to investigate sleep; it leaves the result for any particular sermorelin preparation unsettled.

A controlled sermorelin study with sleep as its endpoint would address these accounts directly. The effects page puts the reports together without turning their prominence into measured odds or a personal expectation.

What about testosterone, muscle and aging?

Sermorelin acts on the GH/IGF-1 system. The older-men study established increases in GH and IGF-1 after 14 days; it did not establish testosterone treatment, muscle growth or broad anti-aging benefits. The tesamorelin cognition and body-composition trial tested a different GHRH analog.

I’d like an adult benefit claim to name the outcome it expects to improve. Energy, strength, sleep and a hormone marker are different outcomes. The editorial challenging secretagogues for aging is useful precisely because it asks the larger clinical question.

Is three months an established sermorelin cycle?

The record offers no established adult course length. The 14-day endocrine study and the first-year pediatric growth trial chose observation periods suited to their own endpoints. A fixed three-month cycle cannot be inferred from them.

The study-amounts page also answers mL, acetate and glycine queries. Its figures describe what named studies administered, with no personal dosing schedule.